Warren Buffett is Selling These 3 Stocks in 2022

In this article, we discuss 3 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 6 Stocks in 2022. 

3. Royalty Pharma plc (NASDAQ:RPRX)

Number of Hedge Fund Holders: 21

Stake Discarded in Q1 2022: 83%

Royalty Pharma plc (NASDAQ:RPRX) is a New York-based firm that buys biopharmaceutical royalties and funds innovations in the biopharmaceutical industry in the United States. It makes drug candidates for various therapeutic areas including rare diseases, cancer, neurology, infectious diseases, hematology, and diabetes.  

Securities filings for Q1 2022 reveal that Warren Buffett sold 83% of his Royalty Pharma plc (NASDAQ:RPRX) stake, holding 1.49 million shares worth $58.2 million. Berkshire Hathaway invested initially in Royalty Pharma plc (NASDAQ:RPRX) in Q3 2021, buying over 13 million shares of the company. 

On May 5, Royalty Pharma plc (NASDAQ:RPRX) reported its Q1 2022 results, announcing an EPS of $0.60, missing estimates by $0.11. The $562 million revenue also fell short of analysts’ predictions by $30.97 million. 

Scotiabank analyst Adam Buckham on May 13 initiated coverage of Royalty Pharma plc (NASDAQ:RPRX) with an Outperform rating and a $53 price target. According to the analyst, Royalty Pharma plc (NASDAQ:RPRX) allows investors diversified access to the biopharmaceutical sector and a “robust” financial profile. Royalty Pharma plc (NASDAQ:RPRX)’s portfolio includes 45 approved and pre-approval products, “which collectively provide investors with exposure to a broad range of therapeutic areas and markers”, the analyst added. 

In Q1 2022, Phill Gross and Robert Atchinson’s Adage Capital Management disclosed a prominent Royalty Pharma plc (NASDAQ:RPRX) stake, with 24.8 million shares worth $967.8 million. In the last quarter of 2021, 21 hedge funds were bullish on the stock, with combined stakes valued at over $2 billion.